Global Semiconductor Rally Surpasses 57 Trillion Assessing the Potential for Further Gains AVAL Q2 2025 Earnings Strong EPS Performance Amid Operational Focus Replimune Secures FDA Agreement on Melanoma Drug Resubmission Path